It is a common perception that approximately 50% of heart failure (HF) patients present with a normal or near-normal left ventricular (LV) ejection fraction ("HF with preserved systolic function"), ...

Patients with either systolic (HFrEF) or diastolic (HFpEF) heart failure usually present in the same way. Common signs and symptoms include the following: worsening fatigue; dyspnea on exertion, which ...

Chicago, IL - Prolongation of the QRS interval, an electrocardiographic marker for ventricular dyssynchrony, is present in more than a third of low-LVEF patients hospitalized for acute heart failure ...

The heart is a muscle like no other, beating 60 to 100 times per minute on average, around the clock. But when it grows weak, it can lead to serious problems: from debilitating shortness of breath and ...

Peripartum cardiomyopathy (PPCM) is a rare but life-threatening condition that can affect women with previously healthy ...

The SGLT2 inhibitor medicines have changed how heart failure is managed. Originally sodium-glucose cotransporter 2 (SGLT2) inhibitors were used to lower blood sugar levels in people who have type 2 ...

Seastar Medical Holding Corporation (($ICU)) announced an update on their ongoing clinical study. Seastar Medical Holding Corporation (ICU) is ...

Heart failure occurs when the heart can't pump blood as well as it should. It can affect either the left side of the heart (left-sided heart failure) or the right side (right-sided heart failure).

The Phase 2b SEISMiC Extension Study showed istaroxime significantly improved systolic blood pressure over six hours compared to placebo. Windtree plans to present detailed study findings, including ...

CRT is a surgical procedure in which doctors implant a pacemaker in both the right and left sides of the heart to help your heart’s chambers beat together. The goal is to improve heart pumping ...

Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. The American Heart ...

On Wednesday, Windtree Therapeutics, Inc. (NASDAQ:WINT) released topline results from its Phase 2b SEISMiC Extension Study of istaroxime for patients in early cardiogenic shock due to heart failure.